| pubmed-article:9222057 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0031154 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0028902 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C0031140 | lld:lifeskim |
| pubmed-article:9222057 | lifeskim:mentions | umls-concept:C1522701 | lld:lifeskim |
| pubmed-article:9222057 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9222057 | pubmed:dateCreated | 1997-8-26 | lld:pubmed |
| pubmed-article:9222057 | pubmed:abstractText | Seven patients with end-stage renal disease requiring support by continuous ambulatory peritoneal dialysis received once-daily 400 mg oral ofloxacin for 7 days for the treatment of bacterial peritonitis. Serum and peritoneal dialysis fluid (PDF) were collected for assay throughout the course of the study and for 5 days thereafter. Ofloxacin, desmethyl ofloxacin and ofloxacin-N-oxide accumulated over the course of therapy and could still be detected in serum and PDF 5 days after the end of therapy. The mean elimination half-life of ofloxacin in serum was 32 +/- 7 h, desmethyl ofloxacin 45 +/- 26 h and for ofloxacin-N-oxide 44 +/- 15 h. The total mean recovery of ofloxacin and its metabolites from the PDF was 15.4%. This regimen results in serum and PDF concentrations likely to be effective for the treatment of infection for at least 10 days. | lld:pubmed |
| pubmed-article:9222057 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9222057 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9222057 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9222057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9222057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9222057 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9222057 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9222057 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:ReevesD SDS | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:BrownN MNM | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:WhiteL OLO | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:BrownI MIM | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:TomsonC RCR | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:McMullinC MCM | lld:pubmed |
| pubmed-article:9222057 | pubmed:author | pubmed-author:MacGownA PAP | lld:pubmed |
| pubmed-article:9222057 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9222057 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:9222057 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9222057 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9222057 | pubmed:pagination | 829-31 | lld:pubmed |
| pubmed-article:9222057 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:meshHeading | pubmed-meshheading:9222057-... | lld:pubmed |
| pubmed-article:9222057 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9222057 | pubmed:articleTitle | The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis. | lld:pubmed |
| pubmed-article:9222057 | pubmed:affiliation | Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, UK. lesassays@UKnequasaa.win-UK.net | lld:pubmed |
| pubmed-article:9222057 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9222057 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
